Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
4.540
+0.030 (0.67%)
At close: May 22, 2026, 4:00 PM EDT
5.00
+0.46 (10.13%)
After-hours: May 22, 2026, 5:00 PM EDT
Aardvark Therapeutics Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Aardvark Therapeutics stock has a consensus rating of "Buy" and an average price target of $15.44. The average 1-year stock price forecast is 240.09% higher than the current stock price, while the lowest is $3.00 (-33.92%) and the highest is $45 (+891.19%).
Price Target: $15.44 (+240.09%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Aardvark Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 3 | 3 | 3 |
| Buy | 5 | 5 | 5 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $8 → $7 | Strong Buy | Maintains | $8 → $7 | +54.19% | May 15, 2026 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 15, 2026 |
| Morgan Stanley | Morgan Stanley | Hold → Sell Downgrades $7 → $3 | Hold → Sell | Downgrades | $7 → $3 | -33.92% | May 15, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +98.24% | Mar 24, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $35 → $21 | Buy | Maintains | $35 → $21 | +362.56% | Mar 2, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.16M
EPS This Year
-3.74
from -2.93
EPS Next Year
-3.40
from -3.74
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 10.8M | ||||||
| Avg | n/a | 1.2M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.97 | -1.67 | ||||||
| Avg | -3.74 | -3.40 | ||||||
| Low | -4.31 | -5.87 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.